Key clinical point: Guselkumab showed sustained safety and effectiveness for treatment of psoriatic arthritis in biologic-naive patients at 1 year.
Major finding: At 52 weeks, 71% and 75% of patients in two guselkumab treatment groups showed an improvement of at least 20% in ACR measures, compared with baseline.
Study details: The data come from 739 adults with active psoriatic arthritis who were part of the DISCOVER-2 study and randomized to guselkumab or placebo.
Disclosures: The study was supported by Janssen. Many authors reported financial relationships with Janssen and other pharmaceutical companies. Nine of the 15 authors are employees of Janssen (a subsidiary of Johnson & Johnson) and own Johnson & Johnson stock or stock options.
McInnes IB et al. Arthritis Rheumatol. 2020 Oct 11. doi: 10.1002/art.41553.